Table 1. Demographics, Relevant Kidney Transplant and Hepatitis C Parameters and Results of Antiviral Therapy.
CNI: calcineurin inhibitor; DDA: direct-acting antiviral; HCV: hepatitis C virus; HTN: hypertension; KDPI: Kidney Donor Profile Index; KTX: kidney transplant; RNA: ribonucleic acid; SVR: sustained viral response; tCr: terminal creatinine.
| Age at KTX (years) | Gender | Recipient HCV genotype | Prior HCV Therapy | HCV RNA viral load at KTX | Donor KDPI | Donor age (years) | Donor tCr | Time on waitlist | Kidney disease | Recipient liver fibrosis score pre-KTX (stage 0-4) | Result of DAA therapy | |
| Pt. #1 | 58 | M | 1a/1b | No | 3,100,000 | 75% | 48 | 0.92 | 56 days | CNI nephrotoxicity | Stage 2 | SVR |
| Pt. #2 | 55 | M | 1a | Yes | 2,100,000 | 51% | 40 | 0.9 | 40 days | Lithium toxicity | Stage 0 | SVR |
| Pt. #3 | 58 | M | 1a/ 1b | Yes | 4,900,000 | 31% | 24 | 1.08 | 9 days | Hepatorenal syndrome | Stage 0 | SVR |
| Pt. #4 | 61 | M | 1a/ 1b | No | 8,600,000 | 68% | 40 | 1.3 | 109 days | Diabetic /HTN | Stage 2 | SVR |
| Pt. #5 | 64 | M | 2b | No | 23,000,000 | 91% | 51 | 0.5 | 193 days | CNI nephrotoxicity | Stage 1 | SVR |
| Pt. #6 | 56 | M | 1b | Yes | 16,000,000 | 24% | 25 | 1 | 42 days | Diabetic | Stage 3 | SVR |
| Pt. #7 | 63 | F | 1b | No | Pending | 73% | 22 | 0.7 | 3 days | Lupus | Stage 0 | Treatment pending |